BC Innovations | Jun 16, 2016
Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

Hepatic disease INDICATION: Liver fibrosis Mouse studies suggest in vivo reprogramming of liver myofibroblasts into hepatocyte-like cells could help treat liver fibrosis. In a mouse model of the disease, in vivo transduction of myofibroblasts with...
BC Innovations | Mar 20, 2014
Cover Story

A liver divided

Three separate teams have directly converted human fibroblasts to proliferative liver cells and thus eliminated a key drawback of using induced pluripotent stem cells to treat damaged livers-the inability of the resulting differentiated cells to...
BC Innovations | Aug 15, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Direct reprogramming of fibroblasts into induced hepatic stem cells (iHSCs) for liver regeneration iHSCs derived directly from fibroblasts could help treat liver diseases. In culture,...
Items per page:
1 - 3 of 3